VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Ltd.

April 26, 2011 07:00 ET

VentriPoint Diagnostics Ltd. Appoints Dr. Robyn Barst to Scientific Advisory Board

SEATTLE, WASHINGTON--(Marketwire - April 26, 2011) - VentriPoint Diagnostics Ltd. ("VentriPoint") (TSX VENTURE:VPT)(PINK SHEETS:VPTDF) – is pleased to announce that Dr. Robyn J. Barst, Professor Emeritus of Pediatrics, Columbia University, has agreed to join the Company's Scientific Advisory Board.

"Dr. Barst has an extensive clinical and research experience in Pulmonary Hypertension, having been the Director of the Pulmonary Hypertension Center at Columbia University for over 25 years," Dr. George Adams states. "We believe that Dr. Barst will help propel the progress of the VMS application in pulmonary hypertension diagnostics, a market which is valued at well over $1 billion." VentriPoint's pulmonary hypertension database is presently undergoing internal testing and is expected to be ready for clinical validation this summer. Dr. Barst will be assisting the Company in identifying clinical research sites.

Dr. Barst received her undergraduate degree from the University of Rochester, Rochester, NY and her medical degree (Alpha Omega Alpha and the Distinguished Medical Alumnus Award of the School of Medicine) from the University of North Carolina, Chapel Hill, NC. She completed a residency in pediatrics, and two fellowships in pediatric cardiology and pulmonary medicine at Columbia University College of Physicians & Surgeons in New York, NY. Following her training, Dr. Barst was recipient of the AHA Clinician-Scientist Award and the NHLBI Clinical Investigator Award.

Dr. Barst founded the first pediatric and adult pulmonary hypertension center in 1982 at Columbia University and served as its director until 2008. She serves as a scientific advisor to pharmaceutical companies worldwide developing novel drugs for pulmonary hypertension. She is a consultant to the FDA, the EMEA and the NHLBI. She also served as Chair of the AHA's Council on Cardiovascular Disease in the Young.

"I welcome the opportunity to serve on the Scientific Advisory Board of VentriPoint," states Dr. Barst. "I believe VentriPoint's VMS™ presents a solid opportunity, which could prove preferable in many situations where MRI and/or contrast ultrasound cannot be used."

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ diagnostic tool and it is pursuing the US-FDA approval through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Contact Information